← Leaderboards
David Fernando Aguillon
Massachusetts General Hospital
$2,207,981
Attributed
$6,898,433
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.8M · FY2022–25$5M$3.8M$2.5M$1.3M$0
'22
'23
'24
'25
Funding mix
By agency
NIH$6,898,433 · 4
By mechanism
RM1$3,821,618 · 1
RF1$1,969,396 · 1
R01$1,107,419 · 2
Top collaborators
- Yakeel T. Quiroz5 shared
- A Claudio Cuello4 shared
- Joseph Arboleda-Velasquez1 shared
- Nilton Custodio1 shared
- Agustin M. Ibanez1 shared
- Bruce L Miller1 shared
- Katherine Laurel Possin1 shared
- Leonel Tadao Takada1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Yakeel T. Quiroz$18,816,029
- Anne Church Hart$8,456,760
- Cenk Ayata$15,872,648
- Bernard Khor$4,267,406
- Sava Sakadzic$6,785,772
Others in their field
Other Rising Stars on “Alzheimer&Apos”
- Kjetil Bjornevik · Harvard University D/B/A Harvard School Of Public Health$3,280,861
- Yanling Wang · Rush University Medical Center$2,986,919
- William G Mantyh · University Of Minnesota$2,961,521
- Allison Mercedes Caban-Holt · University Of Miami School Of Medicine$2,611,182
- Brian Stephen Appleby · Cleveland Clinic Lerner Com-Cwru$2,482,260
- Noah Ray Johnson · University Of Colorado Denver$2,282,487
Research focus
Alzheimer&AposS DiseaseCognitiveNerve DegenerationCognitive PerformanceMutationColombiaMutation CarrierMagnetic Resonance ImagingCross-Sectional StudiesHeterogeneityAmyloidAutosomal Dominant Alzheimer&AposAutosomeImpaired CognitionBiological MarkersCognitive TestingGeneral HospitalsBostonBrainEarly OnsetFutureGenesInternational
Grant awards (6)
Nerve growth factor (NGF) metabolic dysfunction as a marker of cognitive decline in autosomal dominant Alzheimer's disease$284,072
R01 · FY2025 · AG
Nerve growth factor (NGF) metabolic dysfunction as a marker of cognitive decline in autosomal dominant Alzheimer's disease$195,927
R01 · FY2025 · AG
Nerve growth factor (NGF) metabolic dysfunction as a marker of cognitive decline in autosomal dominant Alzheimer's disease$147,065
R01 · FY2025 · AG
US-South American Initiative for Genetic-Neural-Behavioral Interactions in Human Neurodegenerative Research$480,355
R01 · FY2024 · AG
Resilience to Cognitive Decline and Resistance to Alzheimer's Disease and Related Neurodegenerative Diseases in Individuals from Colombia with Autosomal Dominant Dementias$3,821,618
RM1 · FY2023 · NS
Nerve growth factor (NGF) metabolic dysfunction as a marker of cognitive decline in autosomal dominant Alzheimer's disease$1,969,396
RF1 · FY2022 · AG